Who invests in HR+/HER2− BC

292 investors in 47 companies with HR+/HER2− BC programs (active or past), across 123 private rounds.

Funding timeline

One lane per company, one column per year. Bubble area = round size (USD). Click a company or a bubble for its rounds.

← Scroll to see all years →

Disclosed per year
Active (33)
Discontinued (14)

Graph View

Investors (left), grouped by the stage of their earliest round in this indication; companies (right). One ribbon per investor and company; "(n)" = ribbons. Click a name, a stage or a ribbon for details; Shift-, Cmd- or Ctrl-click adds it to compare.

← Scroll to see all companies →

Active (33)
Discontinued (14)

Not on this map

Current owners of active HR+/HER2− BC programs (other than repurposing) with no traceable private round.

Big pharma and academic (own budget) (25)

AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, BMS (RayzeBio, Inc.), Duke University, Eisai, Eli Lilly and Company, F. Hoffmann-La Roche, Fred Hutchinson Cancer Center, GSK plc, J&J (Ambrx, Inc.), Jiangsu Hengrui Pharmaceuticals, Menarini (Stemline Therapeutics), Menarini Group, Merck & Co., Inc. (MSD), Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche (Genentech, Inc.), Sino Biopharm (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.), Sino Biopharm (Nanjing Chia-tai Tianqing Pharmaceutical), University of Michigan, University of Washington, US National Cancer Institute, Washington University School of Medicine in St. Louis

Other companies (no public data about private funding) (49)

Aminex Therapeutics, Inc., Atossa Therapeutics, BeOne Medicines Ltd. (FKA BeiGene, Ltd.), Beta Pharma (Suzhou), Bicycle Therapeutics plc, BioNTech SE, Celcuity, Celldex Therapeutics, Inc., Changchun GeneScience Pharmaceutical, Chengdu JOYO Pharma, Cogent Biosciences, CSPC Pharmaceutical Group, Debiopharm International SA, EnhancedBio Inc., EtiraRx, Inc. (FKA EtiraRx, LLC), Hinova Pharmaceuticals, IDEAYA Biosciences, Inc., Immutep Limited, Incyte, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., Jiangsu Hansoh Pharmaceutical, Jiangsu Simcere Pharmaceutical, Kind Pharmaceuticals, LeonaBio (FKA Athira Pharma), Luye Pharma Group, Monte Rosa Therapeutics, Inc., Nanjing Sanhome Pharmaceutical, NeoTX Therapeutics Ltd., Oncolytics Biotech Inc., Pearl Scientific LLC, Prelude Therapeutics Incorporated, Puma Biotechnology, Qilu Pharmaceutical Co., Ltd., Relay Therapeutics, RemeGen Co., Ltd., Rigel Pharmaceuticals, Risen (Suzhou) Pharma Tech, RNA Nanotherapeutics LLC, Senex Biotechnology, Inc., Shandong Luoxin Pharmaceutical Group, Shanghai Best-Link Bioscience, Shanghai Henlius Biotech, Inc., Shanghai Pharmaceuticals Holding, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., SystImmune Inc., Theratechnologies Inc., Tolmar, TransThera Sciences (Nanjing), Zhejiang Yangli Pharmaceutical Technology